tbuckley/cabot-search huggingface dataset:
A study into growth and anaemia in children with epidermolysis bullosa
Authors: A. Reimer, M. Hess, A. Schwieger‐Brie, D. Kiritsi, F. Schauer, H. Schumann, L. Bruckner‐Tuderman, C. Has
Journal: British Journal of Dermatology (2020)

Severe subtypes of epidermolysis bullosa (EB) are devastating conditions that cause extremely fragile skin and mucosal membranes and lots of wounds. So far, no cure for EB exists. About 5,000 people in the U.K. and 500,000 people worldwide suffer from different EB types. Apart from skin problems, children with EB often have trouble gaining weight, and they develop anaemia (deficiency of iron). As wound healing works best when the body is strong, researchers needed to see how exactly children with EB grow and what factors may stop them from growing properly. To address this, a research group from the German EB reference centre, has looked back at weight, height and blood measurements of 200 children with EB. 157 had a type of EB called recessive dystrophic EB (RDEB) and 43 had junctional EB (JEB). The researchers calculated growth charts that allowed better comparison with growth of healthy children and can help to find EB‐specific growth patterns. The researchers found that the growth of children with RDEB was impaired from the second year of life (age 18 months+). In JEB, growth resembled that of healthy children. Anaemia was present from the second year of life onwards in RDEB and JEB. Children with RDEB who suffered from anaemia and deficiency of proteins, vitamins and certain minerals in the blood had impaired growth compared to those who did not. A lot of inflammation in the body also compromised the growth of children with EB. The EB growth charts from this study will help doctors and families in making decisions on feeding, like giving extra vitamins or tube feeding. The results are also important now that therapies for EB are being developed, so that we can compare how growth will improve in line with such therapies. The direct results of this study are printable growth charts that can be used throughout the world immediately, to assess and counsel children with EB. This is a summary of the study: Natural history of growth and anaemia in children with epidermolysis bullosa: a retrospective cohort study
Contracted family doctor service in Shanghai Weifang Community Health Service Center
Authors: Yaling Li, Zhaohui Du, Yi Zhu, Lan Tang
Journal: BMJ (2018)

Weifang Community Hearth Service Center started a pilot program of contracted family doctor service in 2011, and the program included 3 stages: 1st stage was the establishment of the health archives of the residents; 2nd stage was the service signed with key groups in the community; 3rd stage was extension of contracted service to whole community. The working mode of responsible family doctor team was formed, and the health service for contracted residents was managed by the family doctor teams. The individualized service was provided to residents according to their different needs. As a trial, the Pediatrics Studio was designed to provide special service for focused group among signed residents. Through a series of measures, the signing rate and the extended prescriptions in Weifang community both ranked the first in Pudong New Area, and the visiting rate by the signed patients increased from 30% to 41%. The preliminary impact of the contracted family doctor service has appeared in Weifang community.


Key words: 
Community health service; Family practitioner; Health services administration
三甲医院在全科医生培养方面的作用及其问题
Authors: 王仲
Journal: BMJ (2011)

全科医生制度终于得到了社会的广泛认同,全科医生的职能首先是“医疗服务”,这一简单的定位也在经过近十年的争论后得到了认可.然而,在认同了全科医生制度,认可了全科医生的医疗职能以后,如何培养出符合这个制度下,能够真正有临床能力的全科医生又成为了我们争论的焦点.国家发展和改革委员会、财政部、卫生部等部委在推动全科医生制度和全科医生培养方面投入了大量财力,并给予了各种有利的政策.但是,全科医生的培训基地应当设在哪里,基地的职能是什么,由什么人来培训,培训什么,目前却不能拿出真正明确的答案.针对全科医学的定位和全科医生的培养,我认为目前还没有到具体执行层面,而是在顶层设计层面。
Treatment stratification in B-cell PTLD after solid organ transplantation (SOT) by international prognostic index (IPI) and response to rituximab: Interim results from the PTLD-2 trial.
Authors: Ralf Ulrich Trappe, Christian Koenecke, Martin H. Dreyling, Christiane Pott, Ulrich Duehrsen, Norbert Meidenbauer, Dennis Hahn, Michael Heuser, Christian Schmidt, Matthias Ritgen, Reiner Siebert, Ilske Oschlies, Ioannis Anagnostopoulos, Heiner Zimmermann
Journal: Journal of Clinical Oncology (2020)

8045 Background: The PTLD-1 trials have established risk-stratified sequential treatment of B-cell PTLD. After rituximab induction, patients (pts) in complete remission (25 %) received rituximab consolidation, while all others received R-CHOP. The PTLD-2 trial tests modified risk-stratification including clinical risk factors. These are the results of the 2 nd scheduled interim analysis (40/60 planned pts). Methods: The prospective, multicenter phase II PTLD-2 trial (NCT02042391) enrols treatment-naïve adult SOT recipients with CD20-positive PTLD. Key exclusion criteria are CNS involvement, ECOG &gt; 2, pregnancy, and severe organ dysfunction or severe, active infection. Treatment consists of rituximab (1400 mg SC; first application 375 mg/m 2 IV) on days 1, 8, 15 and 22. After restaging, pts in CR as well as those in PR with ≤ 2 IPI risk factors at diagnosis (low-risk group) continue with four three-weekly courses of rituximab. Most other pts (high-risk group) receive 4 cycles of R-CHOP-21, while thoracic SOT recipients who progress under rituximab (very-high-risk group) receive six cycles of alternating R-CHOP-21 and R-DHAOx. The primary endpoint (event-free survival in the low-risk group) is not analyzed here. Secondary endpoints presented here are response and overall response (ORR) by computed tomography, overall survival (OS), time to progression (TTP) and treatment-related mortality (TRM) overall and by risk group. Results: 40 pts were recruited at 12 centers (2015 – 2019). 21/40 were kidney, 11 lung, 4 liver, 3 heart, and 1 liver/kidney transplant recipients. Median age was 54 years. 38/40 PTLD were monomorphic and 15/40 EBV-associated. 38 pts were evaluated for response at interim staging: 13 were allocated to the low-risk, 17 to the high-risk and 8 to the very-high-risk group. ORR was 28/30 (93 %, CR: 16/30 [53 %]). With a median follow-up of 1.9 years, the 1-year/3-year Kaplan-Meier (KM) estimates of TTP and OS in the intention-to-treat population (40 pts) were 85 %/80 % and 70 %/70 %, respectively. In the low-risk group, the 2-year KM estimate of OS was 100 %. The frequency of infections (all grades) was 50 %, and TRM occurred in 3/40 pts (8 %). Conclusions: One third of enrolled pts were treated in the low-risk group and the recruitment goal for evaluation of the primary endpoint will likely be reached. Interim efficacy and toxicity data with rituximab SC and modified risk-stratification are encouraging despite the inclusion of 35 % thoracic SOT recipients. Clinical trial information: NCT02042391 .
Integrating models of cognition and culture will require a bit more math
Authors: Matthew R. Zefferman, Paul E. Smaldino
Journal: Behavioral and Brain Sciences (2020)

Abstract We support the goal to integrate models of culture and cognition. However, we are not convinced that the free energy principle and Thinking Through Other Minds will be useful in achieving it. There are long traditions of modeling both cultural evolution and cognition. Demonstrating that FEP or TTOM can integrate these models will require a bit more math.
Surgery vs Endoscopy for Early Treatment of Chronic Pancreatitis—Reply
Authors: Marinus A. Kempeneers, Marco J. Bruno, Marja A. Boermeester
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The effect of initiation factor 4E-binding protein 1 in the cell signaling pathways of breast cancer
Authors: Xiao-fei Wu, Ming-qian Cao, Dian-long Zhang, Hong-shen Chen, Tao Liu, Yu-hong Guo, Bin Wu, Xiao-lan Wang
Journal: BMJ (2011)

The expression of human epidermal growth factor receptor 2 (HER2), serine-threonine kinase (Akt), 4E-binding protein (4EBP1), phophorylated ribosomal protein S6 kinasel (p70S6Kl) and ribosomal protein S6 ( S6) were detected with immunohistochemistry in 48 cases of human breast cancer. Tumors high-expressing HER2 showed higher Akt expression as compared to tumors with negative HER2 (P < 0. 01). Levels of Akt were correlated with the downstream molecules 4EBP1 ( P < 0. 01) and p70S6K ( P < 0. 05 ). 4EBP1 was mainly expressed in poorly differentiated tumors (P <0. 01) and correlated with tumor size ( P < 0. 05) , lymph node metastasis ( P < 0. 01) and locoregional recurrences ( P < 0. 01). Results suggest that 4EBPl may be the main factor in PI-phosphoinositide-3-kinase (PI3K)-Akt-mammalian targot of rapanycin signal transduction pathways, which is associated with grade of malignancy and prognosis of breast cancer.

Key words: 
Breast neoplasms; Signal transduction
Abnormal evaluation of CA19-9
Authors: Chen Li, Yue Sha, Tao Guo
Journal: BMJ (2017)

CA19－9是临床常用的肿瘤指标之一，特别是用于胰腺恶性肿瘤的诊断及随诊中。报道1例自身免疫性胰腺炎，临床表现为腹痛、黄疸及体质量下降，CA19－9明显升高，影像学检查不典型，易与胰腺肿瘤混淆，以探讨CA19－9升高的临床意义及自身免疫性胰腺炎特点。
Impact of combined therapy on quality of life in patients with rheumatoid arthritis
Authors: Li-rong Kang, Ya-bo Sun, Jun-jun Liu, Shu-fang Zhang, Fen-yan Zhang, Yong-fu Wang
Journal: BMJ (2009)

One hundred patients with rheumatoid arthritis (RA) were randomly assigned to the medication group (n=38) or combined therapy group (n=62). The quality of life was investigated through the questionnaire before and after 6 months' therapy. Data showed that there was statistically significant difference between the two groups in physical, social, and emotional functions, and self-recognized health status (19.0±9.1 vs 6.6±4.8, 10.0±6.9 vs 3.8±3.3, 6.6±3.2 vs 3.0±1.8, and 11.4±7.6 vs 5.3±3.4) ( all P<0.05 ). Combined therapy could significantly improve the quality of life in RA patients.

Key words: 
Arthritis, Rheumatoid; Combined therapy
A prospective phase II open-label randomized controlled trial to compare mandibular preservation in upfront surgery to neoadjuvant chemotherapy followed by surgery in operable oral cavity cancer.
Authors: D. Chaukar, P. S. Pai, Pankaj Chaturvedi, Gouri Pantvaidya, Anuja Deshmukh, Deepa Nair, Shivakumar Thiagarajan, Anil D'Cruz, Kumar Prabash, Vanita Noronha, Vijay Maruti Patil, Sarbani Laskar
Journal: Journal of Clinical Oncology (2020)

6518 Background: The study objective was to evaluate the non-Inferiority of survival and ability to preserve mandible with the use of neoadjuvant chemotherapy (NACT) in locally advanced oral cancers compared to upfront surgery alone without compromising survival. Methods: This study was a randomized, single centre, non-inferiority trial. Eligibility criteria included treatment naïve histologically confirmed cancer of the oral cavity; cancers requiring segmental resection for paramandibular disease without clinicoradiological evidence of bone erosion, clinical T2, T3 and T4, any N, M0 as per TNM (AJCC) 7th edition, age at least 18 years; and written informed consent. The patients were randomly assigned (1:1) to receive either upfront surgery followed by adjuvant treatment (Standard arm-SA) or receive two cycles of three drugs NACT (Docetaxel, Cisplatin, 5-Flurouracil) at three weekly interval (Intervention arm-IA). Depending on the response after two cycles, the patient would either receive an additional third cycle or undergo surgery followed by adjuvant treatment as decided by the tumour board. The primary endpoint was mandible preservation rate at 30% in the experimental arm. The secondary end points being Loco regional control and treatment related toxicity. Results: Between September 2010 and April 2013, 68 patients were enrolled and randomized to SA (34 patients) and IA (34 patients) with a median follow-up of 3.6 years (IQR 0.95- 7.05 years). Majority of the patients were T4 (n = 40, 58.8%) In the IA 28 patients had partial response (n = 28,82.4%), with a mandible preservation (Marginal Mandibulectomy) rate of 48% (n = 16/34). There were no close or positive margins in the IA. All patients received adjuvant treatment. The number of recurrences was similar in both the arms. All patients in the IA developed toxicities with the majority developing Grade III-IV toxicities (Grade III: 14, 41.2%, Grade IV: 11, 32.4%) (p = 0.739). The disease free survival (DFS) (p = 0.715, HR 0.911[0.516-1.607]) and overall survival (OS) (p = 0.747, HR 0.899[0.510-1.587]) were similar in both the arms. Conclusions: NACT seems to be a feasible option for mandibular preservation with acceptable toxicities in a select group of patients without compromising survival. However this needs to be tested in a larger phase III randomized trial. Clinical trial information: CTRI/2015/11/006396 .
院前心肺复苏研究中亟待解决的若干问题
Authors: 冯庚
Journal: BMJ (2006)

肺复苏术(cardio-pulmonary resuscitation,CPR)是用于抢救心搏骤停患者的一组急救措施的组合.由于心搏骤停发生后的有效抢救期仅仅为数分钟,使该症的院前急救难度大大增加,这是院前复苏成功率难以提高的首要原因.根据院前急救的特殊性设计和制定科学的、合理的心肺脑复苏技术,多年来一直是院前急救研究中最重要的课题之一。
Interim results of prospective pilot phase II trial of concurrent anti-PD-1 and stereotactic radiosurgery (SRS) for melanoma and NSCLC patients with brain metastases (NCT02858869).
Authors: Mohammad Khurram Khan, Tahseen Nasti, Melinda Lynne Yushak, David H. Lawson, Jeffrey M. Switchenko, David Wallington, Troy Kleber, Khadija Kirmani, Taofeek Kunle Owonikoko, Suresh S. Ramalingam, Rafi Ahmed
Journal: Journal of Clinical Oncology (2020)

e22002 Background: The safety and efficacy of concurrent radiotherapy (SRS) and single agent (anti-PD-1) checkpoint inhibitor have not been established. We report the first results of an interim analysis from a prospective pilot phase II trial of cocurrent anti-PD-1 (pembrolizumab) and SRS for brain metastases Methods: Food and Drug Administration (FDA) and Institutional Review Board (IRB) approval were obtained to conduct a prospective trial with three different radiation dose arms (Arm A: 6 Gray (Gy) in 5 fractions (fx), 9 Gy in 3 fractions, and 18-21 Gy in single fraction) in combination with Pembrolizumab. Patients with not more than 10 brain metastasis who have not received prior brain radiation were eligible. Routine statistical methods were used to estimate control of brain metastases within the irradiated volume (local control, LC), anywhere intra-cranial control (AICC), progression free survival (PFS), and overall survival (OS). RECSIST 1.1 criteria were used to assess. Safety was monitored using NCI CTCAE v 4.0 criteria for toxicity assessment while intracranial and extracranial treatment response was assessed according to RECIST 1.1 criteria. Patients were enrolled from 2017-2020. Results: We report interim analysis from the first 18 patients of planned 36 patients who have completed treatments on each of the three different radiation dose arms (12 patients per arm). All patients received PD1 on day 0, immediately followed by SRS within 2-3 days. At 6 months, the LC (94.0% [CI: 65-99.1]), AICC (70.6% [CI: 43.1-86.65]), PFS (50% [24.5-71]), and OS (77.4% [50.3-90.9]) were higher than expected with either SRS alone or PD1 alone, and appear to be comparable to dual checkpoint, but with much less toxicity. No grade 4 or grade 5 toxicity was noted. The primary endpoint of safety, based on the absence of grade 3 CNS toxicity at 3 months was met with all three radiation dose arms. Overall rate of grade 1-3 toxicity was also within acceptable range. Conclusions: Preliminary prospective results of concurrent SRS and single agent pembrolizumab for brain metastases in melanoma and NSCLC supports this strategy as a safe and promising option compared with dual agent therapy. Clinical trial information: NCT02858869.
乏力-心悸-喘憋
Authors: 于欣, 江伟, 沈敏, 曾学军
Journal: BMJ (2012)

患者男,43岁,因反复乏力、心悸8年,加重伴喘憋1年余,于2011年11月8日收入北京协和医院.患者于2003年4月开始出现乏力、心悸、头晕、大汗,无手抖、消瘦、突眼、多食.多次行心电图提示“心房颤动(房颤)”,从未规律服药.2005年外院诊断“甲状腺功能亢进(甲亢)、房颤”,曾口服甲巯咪唑10 mg、3次/d,1个月后因腹胀停用.2006年心悸、乏力加重,活动耐力逐渐降低,间断服用阿司匹林、酒石酸美托洛尔(倍他乐克)等. 关键词：甲状腺激素抵抗综合征
Superiority of Avatrombopag (AVA) to Placebo (PBO) for the Treatment of Chronic Liver Disease (CLD)-Associated Thrombocytopenia (TCP) in Patients Undergoing Scheduled Procedures: Results of 2 Randomized, PBO-Controlled Phase 3 Studies
Authors: Norah Terrault, Francesco Bibbiani, Yi-Cheng Chen, Namiki Izumi, Zeid Kayali, Jose R. Lazcano Soto, Paul Mitrut, Won Young Tak, Tarek I. Hassanein
Journal: Hepatology (2017)
血尿的临床解读
Authors: 章建东
Journal: BMJ (2008)

血尿是常见的临床表现,约见于40%～50%的肾内、泌尿外科门急诊患者,亦可能是恶性疾病的信号. 血尿按含血量可分为肉眼血尿和镜下血尿.临床上规定:凡新鲜尿离心涂片镜检法红细胞>3个/HPF;直接涂片镜检法红细胞>1个/HPF;或定量法1 h尿红细胞数量>10万;12 h尿Addis计数>50万即可判断为镜下血尿。
Screening of stroke risks among middle-aged and elderly people in Shanghai community general outpatient clinics
Authors: Yiqian Zhu, Jianfeng Luo, Dongdong Chen, Min Zhang, Juan Shou, Rong Xu, Jie Gu, Hua Yang
Journal: BMJ (2018)

Objective
To screen stroke risks among middle-aged and elderly people in community outpatient clinics in Shanghai.


Methods
A stroke risk screening was conducted among people aged 45-75 years selected with convenient sampling method from 10 community health service centers in Putuo district, Yangpu district and Pudong New Area of Shanghai during January to July 2017. The questionnaire and clinical measurement were used for screening. Multivariate logistic regression analysis was used to analyze the risk factors in subjects with high stroke risk.


Results
In this study, 1 094 individuals with high stroke risk were screened out from 1 750 participants (62.5%). The proportion of high risk cases was higher among men (66.7%, 473/709) than that among women (59.7%, 621/1 041) , unmarried, divorced or widowed (75.0%, 90/120) than married or cohabitants (61.6%, 1 004/1 630) , living alone (72.1%, 70/97) than living with others (61.9%, 1 024/1 653) (χ2=8.969, 8.571, 4.081; P<0.01). Compared with non-high-risk subjects, the high-risk subjects had higher BMI, systolic blood pressure, diastolic blood pressure, fasting blood glucose, glycated hemoglobin, total cholesterol, triglycerides, serum creatinine and homocysteine, and were more likely to have carotid plaques or stenosis, the difference was statistically significant (P<0.05). Multiple logistic regression analysis showed that unmarried/divorce/widowed, high BMI, systolic blood pressure, fasting blood glucose, total cholesterol, and carotid plaque or stenosis were positively associated with high stroke risk(OR=2.015, 1.173, 1.013, 1.456, 1.139, 1.026, 2.103; P<0.05).


Conclusions
The proportion of high stroke risk individuals among middle-aged and elderly people is higher in community general practice outpatient clinics in Shanghai. Patients with high BMI, systolic blood pressure, fasting blood glucose and total cholesterol, and carotid plaque or stenosis, as well as those unmarried/divorced/widower should be the subjects for stroke intervention.


Key words: 
Stroke; Middle-aged and elderly; Community health center; High risk
老年自发性脾破裂致短期本周蛋白升高一例
Authors: 薛爱君
Journal: BMJ (2005)

患者女,91岁,于2004年3月2日18:00突发头晕恶心伴呕吐2次急诊入院,血压升高.当时无腹痛、腹泻,无发热.既往有高血压病史,无外伤史.体格检查:体温36℃,血压190/90 mm Hg(1 mm Hg=0.133 kPa),心率78次/min,神志清,精神紧张,颈软,双肺呼吸音清;腹软,肝脾不大,腹无压痛、无包块,腹水征(-);神经系统检查未发现异常.尿常规检查无异常,外周血红蛋白97 g/L.颅脑CT示腔隙性脑梗死.入院后给予降血压(卡托普利、尼莫地平)及对症治疗。
X-ray crystal structure analysis of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), bound to estrogen receptor alpha ligand binding domain.
Authors: Sean W. Fanning, Geoffrey Greene, Maureen G. Conlan
Journal: Journal of Clinical Oncology (2020)

e15647 Background: Antiestrogens are a mainstay of treatment for estrogen receptor positive (ER+) breast cancer in both the adjuvant and the advanced/metastatic settings. Elacestrant is a mixed activity selective estrogen receptor (SER) alpha (ERα) antagonist, acting as a SER modulator (SERM) at low doses and a SER degrader (SERD) at high doses. It has shown activity in hormone sensitive wild type (WT) ERα and insensitive estrogen receptor gene 1 (ESR1) mutation-harboring (Y537S and D538G) ERα breast cancer, both in preclinical models and in clinical studies. It also possesses a unique pharmacology compared to other competitive ER antagonists in its ability to cross the blood brain barrier. Competitive ERα antagonists are typically comprised of a core that sits in the ligand binding pocket and an arm that manipulates the structure to achieve SERM or SERD activities. In these molecules, the arm is attached in the same position as the triphenylethylene core of tamoxifen. However, elacestrant possesses a novel site of attachment. As such, we hypothesized that elacestrant adopts an alternative binding orientation in the ERα ligand binding pocket to achieve its unique pharmaceutical profiles. Methods: X-ray crystallography was used to solve a co-crystal structure of elacestrant in complex with WT ERα ligand binding domain to 2Å. Results: Overall, elacestrant promotes the formation of a canonical ERα ligand binding domain antagonist conformation, whereby helix 12 (H12) is docked into the activating function-2 cleft. However, elacestrant adopts a novel vector in the ERα ligand binding pocket that places it in close proximity to helix 12. As a result, it forms a bifurcated hydrogen bond that is not observed in other competitive antiestrogens and samples a chemical space known to increase H12 mobility and induce SERD activity. This novel vector also places it near positions 537 and 538, the two most common sites of somatic mutation. Conclusions: The high-resolution x-ray crystal structure of elacestrant suggests that the unique binding mode it adopts enables novel pharmacology and positions it to achieve potency in the WT and activating somatic ERα mutated breast cancer setting.
海洛因依赖者全麻下超快速脱毒88例
Authors: 敖其尔, 焦士林
Journal: BMJ (2004)

1987年由Loimer等[1,2]建立了快速阿片类脱毒(ROD)技术,1992年西班牙的Legarda等[3]在此基础上创立了超快速阿片类脱毒(UROD)治疗技术,大大减少了阿片类药物成瘾者撤药过程中所耐受戒断症状的痛苦,为快速顺利进入阿片受体拮抗剂的维持治疗奠定了基础.我们采用UROD法观察了88例患者,疗效令人振奋,为广泛开展此脱毒治疗法提供了有力依据。
胃管导入方法体会
Authors: 宋桂兰, 韩鹰鹏, 宋成君
Journal: BMJ (2007)

胃管导入是临床护理工作中的一项基本操作,对于吞咽功能健全的患者,胃管导入一般比效顺利.然而对于因一些中枢性疾病所致吞咽功能下降或丧失的患者,因喉头下咽部肿瘤、烧伤致喉头水肿等疾病所致下咽狭窄畸形的患者,行常规胃管导入十分困难.总结我院1999年1月至2005年12月间行胃管导入的经验,现报告如下。